NCT04475549View on ClinicalTrials.gov

Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

January 23, 2022

Study Completion Date

January 23, 2022

Conditions
MELAS
Interventions
DRUG

IW-6463 Tablets

IW-6463 tablets administered orally (daily)

Trial Locations (5)

10032

Columbia University, New York

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Hospital of DC, Washington D.C.

21205

Johns Hopkins University, Baltimore

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Tisento Therapeutics

INDUSTRY

NCT04475549 - Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) | Biotech Hunter | Biotech Hunter